Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer.

ABSTRACT: The demographic shift toward an older population will increase the number of prostate cancer cases. A challenge in the treatment of prostate cancer is to avoid undertreatment of patients at high risk of progression following curative treatment. These men can benefit from early salvage treatment. An explorative cohort consisting of tissue from 16 patients who underwent radical prostatectomy, and were either alive or had died from prostate cancer within 10 years postsurgery, was analyzed by mass spectrometry analysis. Following proteomic and bioinformatic analyses, major vault protein (MVP) was identified as a putative prognostic biomarker. A publicly available tissue proteomics dataset and a retrospective cohort of 368 prostate cancer patients were used for validation. The prognostic value

SUBMITTER: Ramberg H 

PROVIDER: S-EPMC8163044 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature